Zurich, Switzerland and New Delhi, India, March 27, 2018.ChromaCon and YMC India announced today that they have entered into a Distribution Agreement. Under this agreement, YMC India will act as distributor and provide after-sales service and application support for Contichrom systems in India.The Contichrom line of products consists of FPLC and HPLC systems with advanced process technology. The Contichrom CUBE and CUBE Combined are FPLC systems for the purification of biopharmaceuticals, giving access to superior continuous chromatography processes. The Contichrom HPLC provides the same benefits for peptide and small molecule applications. The recently launched Contichrom Discovery automates and simplifies multi-step purifications of protein and antibodies at R&D scale.Michael Bavand, CEO of ChromaCon commented: “The Indian biotech industry is very strong, especially in bioprocessing of antibodies and production of peptides. With YMC India we now have a valuable partner, who can address the needs of these customers for local representation of our Contichrom systems. We look forward to leveraging both of our companies’ expertise to benefit pharma and biotech customers in India.” About ChromaCon ChromaCon AG is a private Life Science Tool company located in Zürich, Switzerland, providing best-in-class process solutions to the biopharmaceutical industry. ChromaCon has developed and patented novel process principles, process control and simulation software, equipment designs and operating software for batch, cyclic and continuous chromatography. These process solutions result in significant CAPEX and OPEX cost savings and enabling scalable chromatographic solutions for large scale purification applications. The Contichrom® laboratory-scale equipment is co-marketed worldwide by ChromaCon and its partners. ChromaCon has provided global licenses for its process technologies to LEWA for implementation into scale-up systems. ChromaCon also develops and markets affinity purification solutions for column and membrane chromatography applications and tools for site-specific protein conjugation. ChromaCon Contact To find out more about ChromaCon please contact us directly or visit our website. Dr. Michael Bavand, CEO, [email protected], www.chromacon.com. About YMC India Pvt. Ltd. YMC India was established in 2008 with a vision to create a brand value by delivering the BEST Quality of Product, Service & Support to its customers. YMC India has created and maintained an environment where close relationship, between YMC and its end users, is nurtured and grown with benefits to each other – a perfect example of symbiotic relationship.
Bio-Works has opened a sales office in Philadelpia, USA to meet the large demand for separation and purification products for the production of biological medicine in the American market. To be able to support the customers at the right competence level the office will initially be manned with Swedish personnel. Bio-Works will during this year start to build a network of local sales people who will in the future manage the customer relations in USA and Canada.
Mats Johnson, Bio-Works CEO:
”While South Korea is the single most important market for biosimilars, not the least in Asia, USA is the single most important market for agarose based purification of biomolecules for production of original biopharmaceuticals. Many of the original biopharmaceuticals are developed in the US and the rest of the world often copies how the production is done there. Thus it is strategically important to have a good position in the American market. With the establishment of our American office, in combination with our on-going sales activites together with Amicogen in South Korea, we have a good coverage of prioritized markets.”
About Bio-Works
Bio-Works designs, develops, manufactures and supplies innovative leading edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. The company is staffed by people with long experience in the biotech industry and particularly with protein separation media. Bio-Works’ agarose based high performance products are used for purificationin the life science research phase as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally with our own organization and via distributors. Bio-Works facilities are located in the Uppsala Business Park Uppsala, Sweden. Company processes and a Quality Management System follows the standards of ISO 9001:2008. The Bio-Works’ share is traded on Nasdaq First North in Stockholm. FNCA Sweden AB is the Certified Adviser.
